Aderonke T Abiodun

4 weeks ago | jacc.org | Aderonke T Abiodun |Chengsheng Ju |Catherine Welch |Jennifer Lai

Introduction Fluoropyrimidine chemotherapy agents are used first line in the treatment of many gastrointestinal and other solid organ malignancies globally.1-3 The development of cardiotoxicity can often complicate its use and has various manifestations from asymptomatic electrocardiogram changes to angina, heart failure (HF), myocardial infarction, and sudden cardiac death.4 Baseline cardiovascular disease (CVD) and cardiovascular risk factors are common in patients with gastrointestinal...

Jun 6, 2024 | onlinelibrary.wiley.com | Aderonke T Abiodun |Marianne Jane Shawe-Taylor |Sara Tyebally |Emmanouil Bagkeris

Introduction Fluoropyrimidines including 5-fluorouracil (5-FU) and capecitabine are the third most common cancer treatment class used worldwide.1 They form the basis of chemotherapy treatment for gastrointestinal malignancies, breast, pancreatic and head and neck cancers.2-4 For many patients who develop complications with 5-FU, alternative cancer treatment options are very limited, particularly in colorectal cancer where 5-FU is a backbone of first- and second-line chemotherapy, and...